Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.
暂无分享,去创建一个
B. Zinman | C. Cannon | A. Levin | K. Mahaffey | G. Bakris | T. Greene | M. Jardine | V. Perkovic | D. Wheeler | B. Neal | D. de Zeeuw | H. Heerspink | D. Charytan | C. Pollock | R. Agarwal | Hong Zhang | J. Baldassarre | Jingwei Li | Robert Edwards | A. Levin
[1] G. Filippatos,et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.
[2] F. Cosentino,et al. The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.
[3] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[4] B. Zinman,et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.
[5] B. Zinman,et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.
[6] John M Lachin,et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.
[7] V. Basevi,et al. Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.